Early treatment after @entity64 for the prevention of late XXXX : a report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis.

@entity1 @entity410 @entity64 @entity4677 @entity9326 @entity302
INTRODUCTION: @entity302 in @entity64 @entity1 are a common complication and adversely affect neurological outcome. We tried to perform a trial aimed at preventing the development of @entity410 using levetiracetam. Levetiracetam is assumed to have anti-epileptogenic properties and might be suitable to prevent late @entity302 in @entity64 @entity1 . METHODS: @entity64 @entity1 with a @entity9326 and a modified Rankin score >=  3 or NIHSS >=  6 were treated with either levetiracetam 1500 mg daily divided in two doses or placebo during 12 weeks following @entity64 . Treatment was started within 7 days following @entity64 onset. RESULTS: Only 16 @entity1 were included in this trial. Problems during the execution of this prophylactic trial concerned the assessment of the occurrence of @entity302 , a very slow inclusion rate, the use of anticonvulsive co-medication, continuation of the trial medication after discharge, and the evaluation of possible side effects of the trial medication. DISCUSSION: Due to too few @entity1 , no conclusions could be drawn regarding the ability of @entity4677 to prevent @entity410 . The problems encountered during execution of this trial seem to be inherent to performing a trial aimed at preventing the development of @entity302 in @entity64 @entity1 . CONCLUSIONS: A prophylactic trial in @entity64 @entity1 aimed at preventing @entity410 and @entity302 seems not feasible.
